http://www.marketwatch.com/story/add...k=MW_news_stmp

"We are very encouraged by these data, particularly the effect of ADX48621 on dystonia, a debilitating movement disorder in PD and also in other patients who do not have PD. To our knowledge, no other drug on the market or in development has demonstrated this level of activity in this primate model. Furthermore, the data from the HIC model indicate that, in the long-run, ADX48621 also could be tested as a treatment for the general symptoms of PD, potentially as a complementary drug that would allow doctors to optimize levodopa dosing"

This sounds encouraging. Phase II by the end of this year.